



Dreams

DREAMS project

[D8.6] Creation of the Innovation and Exploitation Board (IEB)

Project Founded by the European Commission

DISSEMINATION LEVEL

PU	Public	☒
SEN	Sensitive	☐



DELIVERABLE INFORMATION	
Deliverable N°	[D8.6.]
Deliverable Title	[Creation of the Innovation and Exploitation Board (IEB)]
WP	[WP8 Project Management]
Lead Beneficiary	Kantify
Contributing partners	Zabala
Type	[R — Document, report]
Due Submission Date	04/2024
Actual Submission Date	22/04/2024

DOCUMENT HISTORY			
DELIVERABLE RESPONSIBLE		[Kantify]	
Contributors	Organization	Reviewers	Organization
Segolene Martin	Kantify	Ane Garcia	Zabala

VERSION HISTORY		
VERSION	DATE	COMMENT
1	31/03/2024	Draft by Kantify
2	12/04/2024	Review 1 by Zabala
3	22/04/2024	Final document

Table of Contents

1 Organisation of the Innovation and Exploitation Board.....	3
1.1 Chairmanship & membership.....	3
1.1.1 Members.....	3
1.2 Meeting frequency.....	3
1.3 Agenda.....	4
1.4 Decision making.....	4
1.5 Minutes.....	4
2 Missions and obligations of the IEB members.....	4
2.1 Missions.....	4
2.2 Tasks.....	4
2.3 Key obligations of the IEB members.....	5
2.3.1 Protection of Intellectual Property.....	5
2.3.2 Handling of Confidential Information.....	5

List of Tables

Table 1. DREAMS IEB members and observers.....	3
--	---

List of Abbreviations

TERM	DEFINITION
EU	European Union
IEB	Innovation and Exploitation Board
KERS	Key Exploitable Results
IPR	Intellectual Property Rights

1 Organisation of the Innovation and Exploitation Board

1.1 Chairmanship & membership

The Innovation & Exploitation Board (IEB) shall consist of the coordinator (Xavier Nissan, CECS), as well as Kantify (Segolene Martin) as co-coordinator, and representatives of each other partner in the DREAMS project, appointed by the partners and validated by the General Assembly during its meeting or by email. CECS and Kantify, as co-coordinator, shall co-chair all meetings of the Innovation & Exploitation Board, unless decided otherwise by a majority of two-thirds.

1.1.1 Members

The following individuals are appointed by the respective consortium partners. Each partner will be entitled to 2 participants (1 IEB member and 1 non compulsory IEB observer). However, only the official IEB member will have voice in case of a vote.

Depending on the topic, one or several members can request the participation of an expert who will participate **in the specific agenda item discussion** for which he/she has been asked to join. The member requesting the participation of the expert will ensure that this person is bound to the same confidentiality rules as the requesting member itself.

Table 1. DREAMS IEB members and observers

DREAMS Partner Organization	IEB member	IEB observer (if applicable)
CECS	Xavier Nissan (XNISSAN@istem.fr)	Imen Mestri (imestiri@genethon.fr)
KANTIFY (Meetsies SA)	Segolene Martin CEO (segolene@kantify.com)	Nik Subramanian CTO (nik@kantify.com)
ZABALA	Javier Uranga (juranga@zabala.es)	-
INSERM (Institut National de la Santé et de la Recherche Médicale)	Stéphane Vassilopoulos (s.vassilopoulos@institut-myologie.org)	Antoine Muchir (a.muchir@institut-myologie.org)
UC (Universidade De Coimbra)	Lino Ferreira (lino.ferreira@uc.pt)	Catarina Santos (anacunhasantos@cnc.uc.pt)
APHP (Assistance Publique - Hopitaux de Paris)	Teresinha Evangelista (t.evangelista@institut-myologie.org)	-
TECHNION (Technion - Israel Institute of Technology)	Shenhav Shemer (Cohen) (shenhavc@technion.ac.il)	-
AFM (Association Française Contre Les Myopathies)	Alexandre Mejat (amejat@afm-telethon.fr)	Juliette Peterka (jpeterka@afm-telethon.fr)
SAMSARA (Samsara Therapeutics Ltd)	John Blackwood (john@samsaratherapeutics.com)	-

1.2 Meeting frequency

The IEB will convene at least annually, with additional meetings scheduled as necessary upon request of a general assembly member.

- Meetings can be held in person or via teleconference, depending on the circumstances.
- Ordinary meetings will be announced within 14 calendar days.
- Extraordinary meetings will be convened within 7 calendar days.

1.3 Agenda

The chairperson of the IEB shall prepare and send each member an agenda no later 7 days preceding the meeting. Any Member of the IEB may add an item to the original agenda by written notice to all of the other members of the body up to the minimum number 3 of days preceding the meeting as indicated below.

1.4 Decision making

Decisions will be made on a consensus basis. In the absence of consensus, the Chairperson may call a vote, requiring a majority to pass.

1.5 Minutes

Minutes of the Innovation & Exploitation Board meetings, once accepted, shall be sent by Kantify to the General Assembly Members for information and/or validation.

2 Missions and obligations of the IEB members

2.1 Missions

- The Innovation & Exploitation Board (IEB) will define the protection and exploitation strategy of the DREAMS project results.
- The General Assembly shall request advice of the IEB regarding the protection, management and exploitation strategy of the results generated.
- The IEB will provide advice to the project partners, through the General Assembly, regarding the protection, management and exploitation strategy of the project results and the corresponding business model. It will give advice to the partner on transfer of ownership notifications received by another partner.
- The IEB will establish and update an Intellectual Property Directory, that will list all results and make explicit the owners and the related protection in place.

2.2 Tasks

The Innovation & Exploitation Board will:

- Perform a constant market analysis to benchmark the project's key results according to the state of the art and competitive landscape.
- Develop and update the project's Exploitation and Innovation Plan,
- Monitor progress towards innovation and exploitation goals,
- Provide advice and support to General Assembly on matters related to publication, intellectual property, commercialization strategies, and market analysis.
- Establish an Exploitation plan that will be based on a step-by-step approach:
 - Identification and description of Key Exploitable Results (KERs)
 - Business model generation for project's KERS.

- Business plan development. This will include, if necessary, the coordination with WP6 efforts related to the clinical trial.
- Find potential partners for development of the Result / future clinical trial.

2.3 Key obligations of the IEB members

2.3.1 Protection of Intellectual Property

IEB members recognize the importance of protecting the intellectual property rights (IPR) arising from the project's research and innovation activities. All IEB members commit to refrain from publicly disclosing any information that could compromise the protection of intellectual property rights (either existing or new) until appropriate protective measures are taken. This information includes but is not limited to: promising or validated therapeutic targets, promising or validated molecules and their properties or mode of action, promising or validated therapeutic indications.

2.3.2 Handling of Confidential Information

2.3.2.1 Meeting Deliberations

The discussions, deliberations, and materials presented during IEB meetings are confidential and should be treated as such by all members. This includes, but is not limited to, discussions on:

- Potential intellectual property and patent strategies.
- Specifics of commercialization and market entry strategies.
- Identification and analysis of potential stakeholders and partners.

2.3.2.2 Responsibility of Consortium Members

By appointing a representative to the IEB, each DREAMS partner ensures that its representative will respect and adhere to the confidentiality obligations applicable to all members of the consortium. These obligations, as described in the projects Consortium Agreement include:

- Maintaining the confidentiality of discussions, decisions, and documents related to the IEB meetings.
- Ensuring that any confidential information obtained through participation in the IEB is not disclosed to unauthorized individuals or used for any purpose outside the scope of the project